Your institution may have access to this item. Find your institution then sign in to continue.
Title
A comeback for anti-CD3s in type 1 diabetes?
Abstract
The article focuses on the follow-up trial of teplizumab conducted by Kevan Herold of Yale University and his colleagues after the failure of the Phase III CD3 trial for type-1 diabetes of Lily and Macrogenics.